Compare ACRS & NMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACRS | NMCO |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 512.4M |
| IPO Year | 2015 | 2019 |
| Metric | ACRS | NMCO |
|---|---|---|
| Price | $3.45 | $8.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $9.82 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 598.3K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $8.33 |
| 52 Week High | $6.60 | $11.00 |
| Indicator | ACRS | NMCO |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 36.93 |
| Support Level | $3.24 | $8.33 |
| Resistance Level | $4.60 | $9.16 |
| Average True Range (ATR) | 0.28 | 0.15 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 17.03 | 15.84 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.